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Edited by Miguel De la RosaAbstract Steﬁn A (Stfa) acts as a competitive inhibitor of
intracellular papain-like cysteine proteases which play important
roles in normal cellular functions such as general protein turn-
over, antigen processing and ovarian follicular growth and mat-
uration. In the mouse there are at least three diﬀerent variants of
Stfa (Stfa1, Stfa2 and Stfa3). Recent genetic studies identiﬁed
structural polymorphisms in Stfa1 and Stfa2 as candidates for
Aod1b, a locus controlling susceptibility to day three thymec-
tomy (D3Tx)-induced autoimmune ovarian disease (AOD). To
evaluate the functional signiﬁcance of these polymorphisms, re-
combinant allelic proteins were expressed in Escherichia coli,
puriﬁed and characterized. The polymorphisms do not markedly
alter the folding characteristics of the two proteins. Stfa1 and
Stfa2 both act as fast and tight binding inhibitors of endopeptid-
ases papain and cathepsins L and S, however their interaction
with exopeptidases cathepsins B, C and H was several orders
of magnitude weaker compared to human, porcine and bovine
Stfa. Notwithstanding, the Ki values for the interactions of
Stfa1-b from AOD resistant C57BL/6J mice was 10-fold higher
than that of the Stfa1-a allele from susceptible A/J mice for pa-
pain, cathepsins B, C and H but not L and S. In contrast, the
inhibitory activities of Stfa2-a and Stfa2-b were found to be
roughly equivalent for all targets peptidases.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The thymus is the primary site of T-cell development [1] and
its removal from 3-day-old mice (day 3 thymectomy – D3Tx)
leads to a loss of peripheral tolerance and the development
of organ-speciﬁc autoimmune diseases during adulthood.
D3Tx does not lead to autoimmune disease in all mouse
strains, indicating that the development of these diseases is
genetically controlled [2]. For example, A/J mice are highly
susceptible to autoimmune ovarian disease (AOD) whereas
C57BL/6J mice are not. Previously, using quantitative trait lo-
cus (QTL) linkage analysis we identiﬁed ﬁve regions of the
mouse genome harboring loci (Aod1–Aod5) controlling suscep-
tibility to AOD and its intermediate phenotypes, anti-ovarian
autoantibody production, oophoritis, and atrophy [3]. Subse-*Corresponding author. Fax: +386 1 477 3984.
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two linked loci with opposing allelic eﬀects on disease suscep-
tibility (Aod1a and Aod1b) and lead to the identiﬁcation of
structural polymorphisms in Steﬁn A1 (Stfa1) and A2 (Stfa2)
as candidates for Aod1b.
Steﬁns A (Stfa) are non-glycosylated intracellular inhibitors
of cysteine cathepsins [4] including cathepsin S and L. Cathep-
sins S and L plays an important role in antigen processing and
presentation [5] and cathepsin S has been shown to play a role
in the development of D3Tx-induced autoimmune disease [6].
Additionally, cathepsins are involved in ovarian follicle growth
and maturation [7]. They exhibit complex temporal and spacial
expression patterns at diﬀerent stages of the estrous cycle and
follicular development consistent with divergent functions for
speciﬁc cathepsins in follicular development, growth and rup-
ture [8]. In contrast to human, at least three diﬀerent Stfa vari-
ants are encoded within the mouse genome (Stfa1, Stfa2, and
Stfa3) [9]. They share 60–65% identity in amino acid sequences
and 55–60% identity when compared to human Stfa.
The structural polymorphisms that distinguish the C57BL/6J
(Stfa1-b and Stfa2-b) and A/J (Stfa1-a and Stfa2-a) alleles may
inﬂuence the folding properties and/or their aﬃnity of binding
to their target proteases. In order to evaluate the functional
signiﬁcance of these polymorphisms all four variants of mouse
Stfa were expressed and their interaction constants with pa-
pain and a variety of cysteine cathepsins were determined.
The alleles of Stfa1 and Stfa2 were essentially equivalent as
functional inhibitors of several papain-like cysteine proteases;
however, the Stfa1-a and Stfa2-a alleles have a detectable im-
pact on their interaction with these proteases compared to
Stfa1-b and Stfa2-b.2. Materials and methods
2.1. Materials
Plasmids and expression strains forbacterial andyeast expressionwere
from Novagen and Invitrogen, respectively. Restriction endonucleases
and other molecular biology enzymes were from New England Biolabs.
Ion-exchangeandgel-ﬁltration carrierswere fromAmershamPharmacia
Biotech. Fluorogenic substrates were fromBachem, other chemicals and
salts used in experiments were from Serva. cDNA clones for mouse
cathepsin L (clone ID: IRAKp961H028Q2) and cathepsin S (clone ID:
IMAGp998M103751Q3) were obtained from RZPD (www.rzpd.de).
2.2. Cloning, expression and puriﬁcation of mouse steﬁn A variants
The cDNA clones for mouse Stfa1 and Stfa2 were ampliﬁed by poly-
merase chain reaction (PCR). The PCR products were digested with
NdeI and BamHI and subcloned into pET-3a or pET-11a expression
vector.blished by Elsevier B.V. All rights reserved.
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Cells transformed with recombinant plasmids were grown at 37 C in
Luria-Bertani (LB) medium, containing 100 lg/ml ampicillin and
50 lg/ml chloramphenicol to OD600 0.6. Expression was induced by
addition of isopropyl b-D-thiogalactoside (IPTG) to a ﬁnal concentra-
tion of 0.4 mM. After 1–4 h of induction, the cells were harvested by
centrifugation and resuspended in the ice-cold lysis buﬀer (50 mM
Tris–HCl, 0.1 M NaCl, 1 mM EDTA, pH 8). Cell disruption was
achieved by freezing and thawing of the cell suspension and by soniﬁ-
cation. Nucleic acids were precipitated by the addition of 5% solution
of polyethyleneimine to a ﬁnal concentration of 0.1% and removed to-
gether with the insoluble fractions of bacterial cells by centrifugation.
Clear cytosolic fraction was concentrated and loaded onto a Superdex
G-75 gel ﬁltration column equilibrated in 30 mM Tris–HCl, 0.3 M
NaCl, pH 8.0. Eluted fractions were analyzed by sodium dodecyl sul-
fate–polyacrylamide gel electrophoresis (SDS–PAGE). Fractions con-
taining recombinant protein were collected, dialyzed against 30 mM
Tris–HCl, pH 8, and applied onto a SP-Sepharose Fast Flow column
equilibrated with the same buﬀer. The elution was carried out with a
linear gradient of NaCl (0–0.5 M) in the starting buﬀer. Fractions con-
taining pure protein, as judged by SDS–PAGE analysis, were pooled
and concentrated.
2.3. Cloning, expression and puriﬁcation of mouse cathepsins L and S
The cDNA region encoding mouse procathepsins L and S were
ampliﬁed by PCR. Ampliﬁed DNA products were digested with XhoI
and NotI and ligated into pPIC9 expression plasmid. The recombinant
plasmids were subsequently linearized with SalI and electroporated
into Pichia pastoris strain GS115 using Gene Pulser (Bio-Rad). The re-
combinant clones of P. pastoris were selected on MD agar plates. The
integration of recombinant plasmid into the genome of P. pastoris was
additionally examined by the yeast colony PCR as described in [10]. 40
recombinant clones were tested for protein production using small
50 ml bioreactors (TPP). The clone with the highest level of protein
production, as judged by the SDS–PAGE analysis, was selected for
large-scale expression.
Mature mouse cathepsin S was puriﬁed from the expression media
using ion-exchange chromatography step on SP-Sepharose Fast Flow
equilibrated in 30 mM sodium acetate, 1 mM EDTA, pH 5.5. Proteins
were eluted using linear gradient of NaCl (0–0.5 M) in the starting buf-
fer. Fractions containing cathepsin S were additionally puriﬁed on
Superdex G-75 gel ﬁltration column.
Crude expression media containing mouse procathepsin L was dia-
lyzed against 30 mM Tris–HCl, 1 mM EDTA, pH 7.5 buﬀer and
loaded onto a Q-Sepharose Fast Flow column. Procathepsin L con-
taining fractions were eluted with equilibration buﬀer containing
0.5 M NaCl, dialyzed against 30 mM sodium acetate, 1 mM EDTA,
2 mM DTT, pH 5, and applied onto SP-Sepharose Fast Flow ion ex-
change column equilibrated with the same buﬀer. Pure fractions of ma-
ture cathepsin L were eluted using equilibration buﬀer containing
0.3 M NaCl.
2.4. Circular dichroism spectroscopy
The protein was dissolved in the 10 mM phosphate buﬀer, pH 5.5, at
concentration of 0.5 mg/ml. The far-UV CD spectra were measured at
room temperature (22 C) on the Aviv 60DS spectrometer (Piscata-
way, NJ, USA). Data points were recorded from 250 to 190 nm using
1 nm interval and a cell path length of 0.1 cm. The bandwidth was set
to 1 nm.
2.5. Kinetics of inhibition
In all kinetic experiments, papain, cathepsin S, cathepsin H and
cathepsin B were assayed using 0.1 M phosphate buﬀer, pH 6.0, con-
taining 3 mM DTT and 1 mM EDTA, whereas for cathepsin C,
100 mM NaCl was added into assay buﬀer. Cathepsins L was assayed
in 0.1 M acetate buﬀer, pH 5.5, containing 3 mM DTT and 1 mM
EDTA. The active concentration of enzymes was determined by active
site titration using cysteine protease inhibitor E-64 or human recombi-
nant Stfa pretitrated with papain.
All inhibition experiments were performed under the pseudo ﬁrst-or-
der conditions with inhibitor concentration at least 10-fold higher than
the enzyme concentrations and less than 10% of substrate was hydro-
lyzed during these experiments. Stfa variants were in various concen-
trations mixed with substrate solution dissolved in the appropriatebuﬀer in the ﬂuorometric cuvette. The reaction was initiated by the
addition of enzyme in a negligible volume. Constant concentrations
of papain (50 pM), cathepsin L (30 pM), cathepsin S (60 pM), cathep-
sin C (100 pM), cathepsin H (300 pM) and cathepsin B (100 pM) and
substrates (10 lM Z-Phe-Arg-MCA for papain, cathepsin L, cathepsin
B and cathepsin S and 10 lM Z-Arg-MCA for cathepsin H) were used
throughout the measurements. The progress curves were monitored at
excitation and emission wavelengths of 370 and 460 nm, respectively,
using a C-61 ﬂuorimeter (Photon Technology International).
In all cases, typical biphasic curves were observed and were analyzed
by the least-square ﬁtting to the appropriate equation [11]. Linear
dependence of pseudo ﬁrst-order rate constant against the inhibitor
concentration was observed for all enzyme-inhibitor pairs. Apparent
association rate constants, kass, were obtained from these plots and
were additionally corrected for substrate competition using adequate
Km values. Kdiss were obtained from the intercepts of slopes with the
ordinate and Ki values were calculated from the obtained kass and kdiss
values. If the intercept was too close to the origin of the axis, preclud-
ing an accurate determination of kdiss, Ki values were determined by
the equilibrium method [12]. In these cases, kdiss values were calculated
from kdiss = Ki/kass.3. Results and discussion
3.1. Location of polymorphisms within Stfa1 and Stfa2 alleles
The sequences of the C57BL/6J and A/J Stfa1 and Stfa2 al-
leles are homologous to human Stfa. They posses all secondary
structural elements constituting the fold of steﬁns, the N-termi-
nal helix and four stranded beta sheets, as well as the structural
features crucial for eﬀective binding to the active sites of their
target proteases (Fig. 1, using human Stfa nomenclature), the
N-terminal trunk, the ﬁrst hairpin loop with the characteristics
of QVVAG motif (where the ﬁrst V47 can be replaced by A
and the A49 by Q) and the second hairpin loop [13,14].
The N-terminal trunk of Stfa1-a is one amino acid shorter
than Stfa1-b, whereas the Stfa2-a and Stfa2-b alleles both pos-
sess a seven residue long N-terminal extension when compared
to human Stfa. As can be seen from the theoretical models of
Stfa1 and Stfa2, most variable positions are located in the re-
gions distant to the active site cleft (Fig. 2). Among the vari-
able positions only positions 2 (S2 Stfa1-b – M2 Stfa1-a
substitution) and 3 (L3 Stfa1-b – Y3 Stfa1-a, I3 Stfa2-b –
M3 Stfa2-a substitution) at the N-terminal trunk and position
47 within the ﬁrst hairpin loop, where V47 has been changed to
A in Stfa1-a, are contributing to the direct interactions with
the active site of the target enzymes. This short analysis sug-
gests that there are likely no signiﬁcant diﬀerences in folding
properties between the predominant and variable forms of
mouse Stfa, whereas a possibility exists that there are diﬀer-
ences in their binding aﬃnities primarily due to variability of
the N-terminal trunk region.
3.2. Folding of mouse Stfa1 and Stfa2
Stfa1 and Stfa2 from C57BL/6J and A/J mice were expressed
in E. coli using a vector for cytosolic expression. Formation of
appropriately folded structures was veriﬁed by assessing their
far UV-CD spectra (Fig. 3). The spectra of Stfa2 markedly dif-
fer from the spectra of Stfa1 in that they exhibit an increased
negative molecular ellipticity between 210 and 220 nm and de-
creased molecular ellipticity at lower wavelengths. This diﬀer-
ence is indicative of an increase in disordered structure which is
presumably due to the elongated N-terminal trunk of Stfa2.
Aside from this diﬀerence, the spectra for Stfa1 and Stfa2
are similar to human Stfa spectra. Furthermore, the spectra
Fig. 1. Alignment of amino acid sequences of human Stfa and mouse C57BL/6J and A/J Stfa1 and Stfa2. The location of Stfa1 and Stfa2
polymorphisms from A/J strain of mice are shaded. Secondary structure elements and N-terminal trunk, the ﬁrst and the second hairpin loops are
marked.
Fig. 2. Comparison of three-dimensional models of mouse C57BL/6J (Stfa-b) and A/J (Stfa-a) Stfa1 (left) and Stfa2 (right) with human Stfa. Models
of mouse Stfa variants were produced by homology modeling approach using crystal structure of human Stfa as a template [14]. Main chain worm
model of human Stfa is shown in gray, whereas main chains of mouse steﬁn models are shown in yellow and green, respectively. The amino acid
polymorphisms from A/J strain are presented with red sticks. Polymorphisms located at the protease interaction regions are labeled.
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ing that the polymorphisms do not markedly alter the folding
characteristics of the two inhibitors.
3.3. Inhibitory properties of mouse Stfa1 and Stfa2
To explore the inhibitory properties of Stfa1 and Stfa2 their
interaction constants with several diﬀerent target proteases,
cathepsins L, S, H, B, C and papain were determined (Table
1). Both Stfa1 and Stfa2 were found to act as fast and tight
binding inhibitors of endopeptidases cathepsins L and S and
papain, although the inhibition constants are slightly higher
than those reported for Stfa from other species [15–17]. In con-
trast more pronounced diﬀerences were observed in the inter-
action of Stfa1 and Stfa2 with exopeptidases.Interactions of cystatins with these exopeptidases are in gen-
eral weaker, but still within the low nanomolar range [15–18].
Exopeptidases cathepsins B, H and C poses unique structural
features that restrain binding of substrates and inhibitors to
the parts of the active site cleft [19]. These features compete
with inhibitors for binding into the same sites on the surface
of target proteases. According to the model of cystatin-pa-
pain-like protease complex N-terminal trunk competes with
the features of aminopeptidases: the mini-chain of cathepsin
H [20] and the exclusion domain residues of cathepsin C
[21], whereas the second hairpin loop competes for binding
with the occluding loop of carboxypeptidase cathepsin B [22].
In contrast to the Ki values for human, porcine and bovine
Stfa as reported previously, inhibition of exopeptidases by
Fig. 3. Far ultraviolet spectra of human Stfa and mouse C57BL/6J
and A/J Stfa1 and Stfa2.
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In general mouse Stfa2 was a better inhibitor of mouse cathep-
sin B, human cathepsins C and porcine cathepsin H than
mouse Stfa1. These data suggest that mouse Stfa1 is not a par-
ticularly good inhibitor of papain-like exopeptidases (Ki values
are in micromolar range), whereas Stfa2 inhibits cathepsins H
and C in the nanomolar range and cathepsin B in the micro-
molar range.
Mutational analysis of the second binding loop residues of
human Stfa showed that the most signiﬁcant contribution to
the inhibitory activity is provided by residue L73 building
hydrophobic interactions with the conserved side chain of
W177 papain located at the bottom of S1 0 subsite [23]. ItsTable 1
Kinetic and equilibrium data for the interaction between C57BL/6J and A/J
Enzyme Inhibitor 106 · kass (M1 s1) 104 ·
Papain Steﬁn A1 C57BL/6J 2.7 ± 0.14 225
Steﬁn A1 A/J ND ND
Steﬁn A2 C57BL/6J 4.5 ± 0.34 16.2
Steﬁn A2 A/J 4.2 ± 0.28 5.5
Cathepsin L Steﬁn A1 C57BL/6J 8.7 ± 0.88 13.6
Steﬁn A1 A/J 7.6 ± 0.66 9.8
Steﬁn A2 C57BL/6J 2.7 ± 0.19 2.8
Steﬁn A2 A/J 2.4 ± 0.10 2.4
Cathepsin S Steﬁn A1 C57BL/6J 8.0 ± 0.56 9.6
Steﬁn A1 A/J 7.8 ± 0.34 5.5
Steﬁn A2 C57BL/6J 7.8 ± 0.24 6.3
Steﬁn A2 A/J 5.6 ± 0.31 6.6
Cathepsin H Steﬁn A1 C57BL/6J ND ND
Steﬁn A1 A/J ND ND
Steﬁn A2 C57BL/6J ND ND
Steﬁn A2 A/J ND ND
Cathepsin B Steﬁn A1 C57BL/6J ND ND
Steﬁn A1 A/J ND ND
Steﬁn A2 C57BL/6J ND ND
Steﬁn A2 A/J ND ND
Cathepsin C Steﬁn A1 C57BL/6J ND ND
Steﬁn A1 A/J ND ND
Steﬁn A2 C57BL/6J ND ND
Steﬁn A2 A/J ND ND
The interaction constants for human, porcine and bovine Stfa are from [15–mutation to glycine decreased the aﬃnity for papain and
cathepsins L and B by 300-fold, 10-fold and 4000-fold, respec-
tively. These results conﬁrm that tight interactions within the
second hairpin loop are more important for interaction with
the exopeptidase cathepsin B than for the endopeptidases
tested. From these data we can conclude that missing L73 in
the sequences of mouse Stfa1 and Stfa2 variants is likely the
cause for weaker inhibition of exopeptidases.
The Stfa1 and Stfa2 polymorphism have a detectable eﬀect
on their interactions with endopeptidases. The Ki values for
the interaction of papain with Stfa1-b is 10-fold higher than
that of Stfa1-a. However, no signiﬁcant diﬀerences between
the alleles were observed for their interactions with mouse
cathepsins L and S. Analysis of the interactions of Stfa1 and
Stfa2 alleles with exopeptidases also reveal diﬀerences in the
inhibitory properties of alleles. The inhibitory activity of
Stfa1-a which is shorter by a single amino acid at the N-termi-
nal trunk for papain, cathepsin H, B and C was 10-times
lower than that of Stfa1-b. This diﬀerence in activity is proba-
bly due to the diﬀerence in the length of the N-terminal trunk
of the two alleles. Truncation of the N-terminal M residue does
not aﬀect the inhibitory properties of human Stfa, while trun-
cation of the ﬁrst two amino acid residues reduces aﬃnities for
papain and cathepsins L and B [17]. The inhibitory activity of
Stfa2-a and Stfa2-b for exopeptidases was found to be roughly
equivalent.
Taken together, we were unable to detect any major diﬀer-
ences in the inhibitory activity of the C57BL/6J and A/J Stfa1
and Stfa2 alleles for cathepsins L and S, the primary endopep-
tidases required for antigen processing [5], or in the inhibitory
activity of the Stfa2-a and Stfa2-b for cathepsins B, C and H.Stfa1 and Stfa2 and papain and cathepsins L, S, B, H and S
kdiss (s
1) Ki (nM) Inhibitor Ki (nM)
± 16.0 8.36 ± 0.390 Human steﬁn A 0.019
87.20 ± 5.030 Porcine steﬁn A 0.174
± 3.9 0.361 ± 0.082
± 0.8 0.130 ± 0.016
± 3.68 0.156 ± 0.029 Human steﬁn A 0.31
± 1.34 0.129 ± 0.014 Porcine steﬁn A 0.02
± 1.64 0.104 ± 0.061 Bovine steﬁn A 0.029
± 0.10 0.102 ± 0.010
± 0.87 0.120 ± 0.069 Porcine steﬁn A 0.053
± 0.25 0.071 ± 0.008
± 1.03 0.081 ± 0.013
± 0.42 0.118 ± 0.023
110.9 ± 1.9 Human steﬁn A 1.3
2400 ± 340 Porcine steﬁn A 0.069
18.9 ± 0.3 Bovine steﬁn A 0.44
43.9 ± 2.0
6108 ± 1675 Porcine steﬁn A 2
>10000 Bovine steﬁn A 1.79
1853 ± 124
2348 ± 130
144.0 ± 14.2 Human steﬁn A 1.1
5340 ± 920
187.1 ± 23.3
51 ± 4,3
18].
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lower than that of Stfa1-b for cathepsins B, C and H, which
function to trim the amino- and carboxy-terminal ends of pep-
tides either before or after binding to major histocompatibility
(MHC) class II molecules [5]. This diﬀerence in activity could
impact the level and nature of antigen speciﬁc peptide-class II
complexes on the surface of antigen presenting cells thereby
selectively altering T cell responses in D3Tx mice in favor of
either susceptibility or resistance to AOD. In addition to their
role in antigen processing, one or more of cathepsins B, C and
H has been implicated in a variety of cellular functions directly
relevant to D3Tx-induced AOD including the regulation of
apoptosis in T and B-cells [24] and in ovarian follicle growth
and maturation [7,8]. Consequently potential diﬀerences in
the expression proﬁles of inhibitors as well as target proteases
should be examined in both inbred strains of mice. Given the
complex temporal and spatial expression patterns of cathep-
sins in both the immune system and the target organ our re-
sults warrant further investigation into the role the C57BL/
6J and A/J Stfa1 alleles in the genetic control of susceptibility
to D3Tx-induced AOD.
We have shown that mouse Stfa1 and Stfa2 act as fast and
tight binding inhibitors of papain-like endopeptidases. Surpris-
ingly they are signiﬁcantly less eﬀective against papain-like cys-
teine exopeptidases than human, porcine and bovine Stfa,
suggesting that in mice Stfa variants are involved predomi-
nantly in the regulation of endopeptidase activity of cysteine
cathepsins. Since cysteine cathepsins play a crucial role in the
antigen presentation processes, these ﬁndings indicate that
the interactions between Stfa and cathepsins contribute to
the species dependent diversity of the endosomal compart-
ments including those involved in immune response.
Acknowledgments: We thank Dr. Igor Stern, M.Sc. Dejan Caglic and
Ivica Klemencic for providing us with cathepsins C, B and cathepsin
H. This work was supported by the Slovenian Research Agency and
by National Institutes of Health Grants AI41747 (to C.T.).References
[1] Bhandoola, A. and Sambandam, A. (2006) From stem cell to T
cell: one route or many? Nat. Rev. Immunol. 6, 117–126.
[2] Tung, K.S.K., Setiady, Y.Y., Samy, E.T., Lewis, J. and Teuscher,
C. (2005) Autoimmune ovarian disease in day 3-thymectomized
mice: the neonatal time window, antigen speciﬁcity of disease
suppression and genetic control. CTMI 293, 209–247.
[3] Roper, R.J., McAllister, R.D., Biggins, J.E., Michael, S.D., Min,
S.H., Tung, K.S., Call, S.B., Gao, J. and Teuscher, C. (2003)
Aod1 controlling day 3 thymectomy-induced autoimmune ovar-
ian dysgenesis in mice encompasses two linked quantitative trait
loci with opposing allelic eﬀects on disease susceptibility. J.
Immunol. 170, 5886–5891.
[4] Barrett, A.J., Rawlings, N.D., Davies, M.E., Machleidt, W.,
Salvesen, G. and Turk, V. (1986) in: Proteinase Inhibitors (Barrett,
A.J. and Salvesen, G., Eds.), pp. 515–569, Elsevier, Amsterdam.
[5] Chapman, H.A. (2006) Endosomal proteases in antigen presen-
tation. Curr. Opin. Immunol. 18, 78–84.
[6] Saegusa, K., Ishimaru, N., Yangi, K., Arakaki, R., Ogawa, K.,
Saito, I., Katanuma, N. and Hayashi, Y. (2002) Cathepsin S
inhibitor prevents autoantigen presentation and autoimmunity. J.
Clin. Invest. 110, 361–369.[7] Carnevali, O., Cionna, C., Lubzens, E. and Maradonna, F. (2006)
Role of cathepsins in ovarian follicle growth and maturation.
Gen. Comp. Endocrinol. 146, 195–203.
[8] Oksjoki, S., Soderstrom, M., Vuorio, E. and Anttila, L. (2001)
Diﬀerential expression patterns of cathepsins B, H, K, L and S in
the mouse ovary. Mol. Hum. Reprod. 7, 27–34.
[9] Tsui, F.W., Tsui, H.W., Mok, S., Mlinaric, I., Copeland, N.G.,
Gilbert, D.J., Jenkins, N.A. and Siminovitch, K.A. (1993)
Molecular characterization and mapping of murine genes encod-
ing three members of the steﬁn family of cysteine proteinase
inhibitors. Genomics 15, 507–514.
[10] Linder, S., Schliwa, M. and Kube-Granderath, E. (1996) Direct
PCR screening of Pichia pastoris clones. BioTechniques 20, 980–
982.
[11] Morrison, J.F. (1982) The slow-binding and slow, tight binding
inhibition of enzyme catalyzed reactions. Trends Biochem. Sci. 7,
102–105.
[12] Greco, W.R. and Hakala, M.T. (1979) Evaluation of methods for
estimating the dissociation constant of tight binding enzyme
inhibitors. J. Biol. Chem. 254, 12104–12109.
[13] Stubbs, M.T., Laber, B., Bode, W., Huber, R., Jerala, R.,
Lenarcic, B. and Turk, V. (1990) The reﬁned crystal structure of
recombinant human steﬁn B in complex with the cysteine
proteinase papain: a novel type of proteinase inhibitor interaction.
EMBO J. 9, 1939–1947.
[14] Jenko, S., Dolenc, I., Guncar, G., Dobersek, A., Podobnik, M.
and Turk, D. (2003) Crystal structure of steﬁn A in complex with
cathepsin H: N terminal residues of inhibitors can adapt to the
active sites of endo- and exopeptidases. J. Mol. Biol. 326, 875–
885.
[15] Lenarcic, B., Krizaj, I., Zunec, P. and Turk, V. (1996) Diﬀerences
in speciﬁcity for the interactions of steﬁns A, B and D with
cysteine proteinases. FEBS Lett. 21, 113–118.
[16] Turk, B., Ritonja, A., Bjork, I., Stoka, V., Dolenc, I. and Turk, V.
(1995) Identiﬁcation of bovine steﬁn A, a novel protein inhibitor
of cysteine proteinases. FEBS Lett. 360, 101–105.
[17] Estrada, S., Pavlova, A. and Bjork, I. (1999) The contribution of
N-terminal region residues of cystatin A (steﬁn A) to the aﬃnity
and kinetics of inhibition of papain, cathepsin B, and cathepsin L.
Biochemistry 38, 7339–7345.
[18] Dahl, S.W., Halkier, T., Lauritzen, C., Dolenc, I., Pedersen, J.,
Turk, V. and Turk, B. (2001) Human recombinant pro-dipeptidyl
peptidase I (cathepsin C) can be activated by cathepsins L and S
but not by autocatalytic processing. Biochemistry 40,
1671–1678.
[19] Turk, D. and Guncar, G. (2003) Lysosomal cysteine proteases
(cathepsins): promising drug targets. Acta. Crystallogr. D Biol.
Crystallogr. 59, 203–213.
[20] Guncar, G., Podobnik, M., Pungercar, J., Strukelj, B., Turk, V.
and Turk, D. (1998) Crystal structure of porcine cathepsin H
determined at 2.1 A resolution: location of the mini-chain C-
terminal carboxyl group deﬁnes cathepsin H aminopeptidase
function. Structure 15, 51–61.
[21] Turk, D., Janjic, V., Stern, I., Podobnik, M., Lamba, D., Dahl,
S.W., Lauritzen, C., Pedersen, J., Turk, V. and Turk, B. (2001)
Structure of human dipeptidyl peptidase I (cathepsin C): exclusion
domain added to an endopeptidase framework creates the
machine for activation of granular serine proteases. EMBO J.
20, 6570–6582.
[22] Musil, D., Zucic, D., Turk, D., Engh, R.A., Mayr, I., Huber,
R., Popovic, T., Turk, V., Towatari, T. and Katunuma, N.
(1991) The reﬁned 2.15 A X-ray crystal structure of human
liver cathepsin B: the structural basis for its speciﬁcity. EMBO
J. 10, 2321–2330.
[23] Pavlova, A. and Bjork, I. (2002) The role of the second binding
loop of the cysteine protease inhibitor, cystatin A (steﬁn A), in
stabilizing complexes with target proteases is exerted predomi-
nantly by Leu73. Eur. J. Biochem. 269, 5649–5658.
[24] Chwieralski, C.E., Welte, T. and Buhling, F. (2006) Cathepsin-
regulated apoptosis. Apoptosis 11, 143–149.
